Vitality Watch

⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.

Mentioned 1× · first seen 20-sep-2026 · last seen 20-sep-2026

GLP-1 Receptor Agonists as Candidate Geroprotectors

Current understanding

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are being reframed from glycemic/weight agents to candidate gerotherapeutics on the basis of RCT mortality and kidney-outcome signals that appear only partially explained by weight or glucose lowering [human-rct], plus first randomized 2025 evidence that semaglutide decelerates validated DNA-methylation aging clocks [human-rct]. Proposed mechanistic substrates span central and peripheral GLP-1R signaling into inflammation, autophagy/mTOR crosstalk, vascular biology, and gut–brain communication [mechanism-plausible]. Definitive aging-endpoint trials do not yet exist, and the biology-to-gerotherapeutic pitch outruns the current evidence base.

Evidence log

Open questions

Related

Contributing findings

pubmed review
GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.
14-sep-2026 novelty 3 per-area 3 introduces
pubmed review expert-opinion
GLP1 Mimetics and Stem Cells: An Intersection of Metabolic and Regenerative Medicine.
18-jul-2026 novelty 3 per-area 3 strengthens

build build 880 · 2bcef25 · 2026-11-18